MARISSA STANKUS: Open Payments
NPI 1700035615 · WATERBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,291 in 59 payments from 15 companies in 2025. Trend: 2023 $418 · 2024 $645 · 2025 $1,291
Food & beverage: $1,291
| Company | Payments | Amount |
|---|---|---|
| Optinose US, Inc. | 7 | $253 |
| GlaxoSmithKline, LLC. | 13 | $207 |
| CSL Behring | 6 | $141 |
| Amgen Inc. | 7 | $140 |
| Novartis Pharmaceuticals Corporation | 7 | $125 |
| Genentech USA, Inc. | 4 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Stryker Corporation | 1 | $46 |
| Pharming Healthcare, Inc. | 2 | $35 |
Products named: Xhance, NUCALA, XOLAIR, TEZSPIRE, Andembry, DUPIXENT, Rhapsido, Haegarda.
Industry payments across CT — which companies pay providers there.
